Biology • Year 12 • Module 7 • Lesson 11

Adaptive Immunity — Antigens and Antibodies

Apply knowledge of clonal selection, antibody mechanisms, and primary vs secondary immune response to real data and scenarios.

Apply · Data & Reasoning

1. Sequence the steps — from antigen exposure to antibody production

The eight events below describe the humoral immune response after a person is exposed to Streptococcus pyogenes (the cause of strep throat). They are shuffled. Write the correct order (1–8) in the Order column. 8 marks

OrderEvent
S. pyogenes surface proteins are processed and displayed on MHC II by a dendritic cell in the lymph node.
IgG antibodies bind to S. pyogenes surface antigens, coating the bacterium (opsonisation).
The selected B cell receives a co-stimulatory signal from a T helper cell that has independently recognised the same antigen.
Plasma cells die off; antibody levels in blood decline over weeks.
The one B cell from millions whose BCR matches the S. pyogenes antigen binds it — clonal selection.
S. pyogenes enters the respiratory epithelium and is phagocytosed by a dendritic cell.
The activated B cell undergoes clonal expansion, differentiating into plasma cells and memory B cells.
Phagocytes with Fc receptors bind the opsonised bacteria and engulf them.
Stuck? Trace the clonal selection flowchart in the lesson — start with the pathogen entering, end with pathogen elimination.

2. Interpret real data — primary and secondary antibody response

The graph below shows serum antibody levels (IgM and IgG combined, arbitrary units) measured in a healthy adult following two exposures to the varicella-zoster virus (chickenpox). The data are adapted from published immunology studies of primary varicella infection and secondary exposure. 10 marks

0 100 200 300 400 500 Serum antibody level (AU) 0 10 20 30 50 60 70 80 100 Day 1st exposure (day 0) 2nd exposure (day 60) Primary peak ~80 AU, day 14 Secondary peak ~420 AU, day 67 Memory B cells persist here
Figure 2.1. Serum antibody titres following two exposures to varicella-zoster virus in a healthy adult. Adapted from immunological data on primary varicella infection and immune memory (Arvin, 1996; Clinical Microbiology Reviews 9:361–381).

2.1 Identify the peak antibody level during the primary response and the day on which it occurred. Calculate the ratio of the secondary peak to the primary peak. 2 marks

2.2 The primary response took 14 days to reach its peak. The secondary response reached its peak by day 67 — only 7 days after the second exposure. Explain this difference at the cellular level. 3 marks

2.3 Between days 35 and 60 (primary response), antibody levels fell to approximately 8 AU, yet the patient responded rapidly to the second exposure. What does this indicate about how immunological memory is stored? 2 marks

2.4 A student claims: "The patient was immune after the first exposure because antibody levels never dropped to zero." Evaluate this claim using the data and your lesson knowledge. 3 marks

Stuck? Revisit the lesson's primary vs secondary response comparison table and the Revisit section on varicella-zoster memory.

3. Spot the errors — what's wrong with this student's antibody diagram?

A Year 12 student drew the diagram below to explain how antibodies defend against pathogens. There are three biological errors. Identify each error and write the correction. 6 marks — 2 per error: 1 identify, 1 correct

Student antibody diagram with errors

3.1 Error 1: What is wrong?

Correction:

3.2 Error 2: What is wrong?

Correction:

3.3 Error 3: What is wrong?

Correction:

Stuck? Compare with the lesson's antibody structure card, the misconceptions box ("antibodies kill pathogens"), and the clonal selection flowchart (which cell produces antibodies).

4. Case study — COVID-19 booster doses and memory

During Australia's COVID-19 vaccination rollout (2021–2022), health authorities recommended booster doses of mRNA vaccines (e.g. Comirnaty / Pfizer-BioNTech) approximately 3–6 months after the primary two-dose series. Studies showed that antibody levels against the SARS-CoV-2 spike protein declined significantly in the months after the primary series, yet recipients of a booster shot showed antibody levels 10–40 times higher than their primary-series peak within 7 days. 5 marks

4.1 Using your knowledge of clonal selection, explain why the primary vaccine series generates both short-term antibody protection and long-term immunological memory. 2 marks

4.2 Explain, at the cellular level, why the booster dose produced a much larger antibody response within 7 days — faster and larger than the primary series response. 2 marks

4.3 A commentator wrote: "If antibody levels fall after vaccination, the vaccine has stopped working." Is this claim biologically justified? Justify your answer in one sentence. 1 mark

Stuck? Think about what is produced alongside plasma cells during clonal expansion, and where the "memory" of the antigen is stored.
Answers — Do not peek before attempting

Q1 — Correct sequence

Correct order: (6) S. pyogenes enters and is phagocytosed → (1) antigens displayed on MHC II by dendritic cell → (5) B cell with matching BCR binds (clonal selection) → (3) T helper co-stimulatory signal → (7) clonal expansion → plasma cells + memory B cells → (2) IgG opsonises bacteria → (8) phagocytes with Fc receptors engulf bacteria → (4) plasma cells die, antibody levels decline.

Award 1 mark for each correctly placed event pair (max 8). Accept minor variation in the ordering of events that logically occur in parallel (e.g. 2 and 8 may be considered simultaneous).

Q2.1 — Primary peak and ratio (2 marks)

Primary peak: approximately 80 AU at day 14. Secondary peak: approximately 420 AU at day 67. Ratio: 420 ÷ 80 = 5.25. The secondary response produced roughly 5× more antibody than the primary response, demonstrating the enhanced effectiveness of immunological memory.

Q2.2 — Cellular explanation of response speed (3 marks)

During the primary response, clonal selection must first identify the rare B cell clone (from millions with different BCRs) whose receptor matches the varicella-zoster antigen [1]. This takes 7–14 days as dendritic cells process and present antigen, the matching naive B cell encounters it, receives a T helper signal, and then undergoes clonal expansion [1]. During the secondary response, memory B cells formed during the primary response are already pre-selected for that antigen — they exist in much greater numbers, are already matched, and activate within hours without needing to search through naive B cells, producing plasma cells and antibodies within 1–3 days [1].

Q2.3 — Where memory is stored (2 marks)

The rapid secondary response despite low circulating antibody levels shows that immunological memory is stored cellularly — in long-lived memory B cells — not as pre-existing circulating antibodies [1]. The memory B cells persisted in lymph nodes and bone marrow through the low-antibody period (days 35–60) and reactivated rapidly on second exposure [1].

Q2.4 — Evaluate the student's claim (3 marks)

The claim is partly correct but misleading [1]. Low residual antibody levels (8 AU by day 60) do offer some baseline protection, but they are insufficient to explain the rapid secondary response — at 8 AU, the antibody titre is too low to neutralise a meaningful viral dose [1]. The real basis of ongoing immunity is the pool of memory B cells (not circulating antibodies), which activate within hours of second exposure and produce new antibodies in large quantities before the virus can establish a significant infection [1].

Q3 — Diagram critique (6 marks)

3.1 Error 1 (circular blob, "binds ANY antigen"): Antibodies are Y-shaped proteins with two identical antigen-binding sites (Fab regions) whose variable region binds only one specific epitope — not any antigen. Correction: redraw as a Y-shape with two Fab arms; label "binds ONE specific epitope (antigen-specific)". [1 + 1]

3.2 Error 2 ("kills bacterium directly"): Antibodies do not kill pathogens directly. They flag the pathogen for destruction by other mechanisms (opsonisation for phagocytosis, complement activation, agglutination, neutralisation). Correction: label the arrow "opsonises / marks for phagocytosis — phagocytes with Fc receptors complete the destruction". [1 + 1]

3.3 Error 3 ("produced by T helper cells"): Antibodies are produced by plasma cells — differentiated B cells that have undergone clonal selection and expansion. T helper cells provide the co-stimulatory signal for B cell activation but do not produce antibodies. Correction: change caption to "Antibodies are produced by plasma cells (activated B cells)". [1 + 1]

Q4.1 — Primary series generates short and long-term immunity (2 marks)

The mRNA vaccine introduces the SARS-CoV-2 spike protein antigen. Clonal selection identifies the B cell clone with a BCR matching the spike protein epitope [1]. After activation and clonal expansion, the clone differentiates into plasma cells (producing antibodies for weeks — short-term protection) and memory B cells (long-lived — the basis of long-term immunological memory) [1].

Q4.2 — Why the booster is faster and larger (2 marks)

The booster dose acts as a second exposure to the spike antigen. The memory B cells formed after the primary series are activated within hours — without needing a new round of clonal selection from naive cells [1]. Memory B cells exist in much larger numbers than the original naive clone and are already pre-selected; they rapidly differentiate into plasma cells producing large amounts of high-affinity IgG, explaining the 10–40× larger response in only 7 days [1].

Q4.3 — Declining antibodies ≠ vaccine failure (1 mark)

No — the claim is not justified: declining antibody levels do not mean the vaccine has stopped working, because immunological memory is stored in long-lived memory B cells that can rapidly regenerate antibody production on re-exposure, even when circulating antibody levels are low. [1]